Latest Insider Transactions at Aerie Pharmaceuticals Inc (AERI)
This section provides a real-time view of insider transactions for Aerie Pharmaceuticals Inc (AERI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AERIE PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AERIE PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2022
|
Raj Kannan Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
215,783
-100.0%
|
$3,236,745
$15.25 P/Share
|
|
Nov 21
2022
|
Jeffrey Calabrese Vice President of Finance |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,585
-100.0%
|
$278,775
$15.25 P/Share
|
|
Nov 21
2022
|
Richard Croarkin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,095
-100.0%
|
$241,425
$15.25 P/Share
|
|
Nov 21
2022
|
Michael Du Toit Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,095
-100.0%
|
$241,425
$15.25 P/Share
|
|
Nov 21
2022
|
David W Gryska Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,996
-100.0%
|
$29,940
$15.25 P/Share
|
|
Nov 21
2022
|
David W Gryska Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,495
-100.0%
|
$172,425
$15.25 P/Share
|
|
Nov 21
2022
|
John La Rocca General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
53,585
-100.0%
|
$803,775
$15.25 P/Share
|
|
Nov 21
2022
|
Peter Frederick Lang Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,297
-100.0%
|
$694,455
$15.25 P/Share
|
|
Nov 21
2022
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
280,244
-100.0%
|
$4,203,660
$15.25 P/Share
|
|
Nov 21
2022
|
Peter J Mc Donnell Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,995
-100.0%
|
$119,925
$15.25 P/Share
|
|
Nov 21
2022
|
Benjamin F Mcgraw Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
41,984
-100.0%
|
$629,760
$15.25 P/Share
|
|
Nov 21
2022
|
Julie Mc Hugh Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,095
-100.0%
|
$241,425
$15.25 P/Share
|
|
Nov 01
2022
|
Jeffrey Calabrese Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
179
-0.95%
|
$2,685
$15.22 P/Share
|
|
Aug 14
2022
|
Jeffrey Calabrese Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
265
-1.39%
|
$2,915
$11.57 P/Share
|
|
Aug 14
2022
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
771
-1.42%
|
$8,481
$11.57 P/Share
|
|
Jul 01
2022
|
Jeffrey Calabrese Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
266
-1.38%
|
$2,128
$8.36 P/Share
|
|
Jul 01
2022
|
Jeffrey Calabrese Vice President of Finance |
BUY
Grant, award, or other acquisition
|
Direct |
11,276
+36.88%
|
-
|
|
Jun 09
2022
|
Richard Croarkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+27.95%
|
-
|
|
Jun 09
2022
|
Michael Du Toit Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+27.95%
|
-
|
|
Jun 09
2022
|
David W Gryska Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+35.2%
|
-
|
|
Jun 09
2022
|
Peter J Mc Donnell Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+43.86%
|
-
|
|
Jun 09
2022
|
Benjamin F Mcgraw Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+12.95%
|
-
|
|
Jun 09
2022
|
Julie Mc Hugh Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,245
+27.95%
|
-
|
|
Mar 18
2022
|
Peter Frederick Lang Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,297
+50.0%
|
-
|
|
Mar 18
2022
|
John La Rocca General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
19,015
+25.92%
|
-
|
|
Mar 18
2022
|
Casey C. Kopczynski Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,015
+6.35%
|
-
|
|
Feb 28
2022
|
Benjamin F Mcgraw Iii Director |
SELL
Payment of exercise price or tax liability
|
Direct |
10,324
-22.41%
|
$82,592
$8.3 P/Share
|
|
Feb 19
2022
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,973
-5.29%
|
$11,838
$6.0 P/Share
|
|
Feb 08
2022
|
Thomas A Mitro President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,111
-1.35%
|
$7,777
$7.33 P/Share
|
|
Feb 08
2022
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
700
-0.27%
|
$4,900
$7.33 P/Share
|
|
Feb 07
2022
|
Thomas A Mitro President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,310
-1.56%
|
$9,170
$7.24 P/Share
|
|
Feb 07
2022
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
768
-2.02%
|
$5,376
$7.24 P/Share
|
|
Feb 07
2022
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
701
-0.27%
|
$4,907
$7.24 P/Share
|
|
Feb 06
2022
|
Thomas A Mitro President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,435
-1.68%
|
$10,045
$7.05 P/Share
|
|
Feb 06
2022
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
384
-1.0%
|
$2,688
$7.05 P/Share
|
|
Feb 06
2022
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
876
-0.33%
|
$6,132
$7.05 P/Share
|
|
Feb 04
2022
|
Thomas A Mitro President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,435
-1.66%
|
$10,045
$7.05 P/Share
|
|
Feb 04
2022
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,206
-3.04%
|
$8,442
$7.05 P/Share
|
|
Feb 04
2022
|
Casey C. Kopczynski Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-0.36%
|
$6,741
$7.05 P/Share
|
|
Feb 04
2022
|
David Hollander Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
927
-2.93%
|
$6,489
$7.05 P/Share
|
|
Jan 30
2022
|
Kathleen Mcginley CHRO & VP, Corp Services |
SELL
Payment of exercise price or tax liability
|
Direct |
878
-3.53%
|
$5,268
$6.92 P/Share
|
|
Dec 20
2021
|
Raj Kannan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
215,783
+50.0%
|
-
|
|
Nov 11
2021
|
David Hollander Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,162
-6.39%
|
$25,944
$12.06 P/Share
|
|
Sep 20
2021
|
Benjamin F Mcgraw Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,513
+42.83%
|
-
|
|
Aug 14
2021
|
Christopher Staten Interim CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
877
-3.88%
|
$12,278
$14.7 P/Share
|
|
Aug 14
2021
|
John La Rocca General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-1.89%
|
$10,710
$14.7 P/Share
|
|
Jun 17
2021
|
Richard Croarkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,750
+15.09%
|
-
|
|
Jun 17
2021
|
Peter J Mc Donnell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,750
+50.0%
|
-
|
|
Jun 17
2021
|
Gerald D. Cagle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,750
+8.03%
|
-
|
|
Jun 17
2021
|
Michael Du Toit Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,750
+15.09%
|
-
|